Tiber Creek Group (on Behalf of Vertex Pharmaceuticals)
Government relations.
Based in DC
AI Overview
With $1.6M in lobbying spend across 29 quarterly filings, Tiber Creek Group (on Behalf of Vertex Pharmaceuticals) is a significant lobbying presence. Their lobbying covers 2 issue areas. Active from 2018 to 2025.
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2018 | $60K |
| 2019 | $80K |
| 2020 | $80K |
| 2021 | $180K |
| 2022 | $320K |
| 2023 | $320K |
| 2024 | $240K |
| 2025 | $280K |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Medicare/Medicaid, Health Issues
Issues related to rare diseases (cystic fibrosis); Issues related to pharmaceutical pricing
Issues related to rare diseases (cystic fibrosis.
Issues related to rare diseases (cystic fibrosis)
Issues related to rare diseases (Cystic fibrosis).
Issues related to pharmaceutical pricing.
Issues related to the Prescription Drug Pricing Reduction Act
Issues related to Part D redesign
Issues related to the Prescription Drug Pricing Reduction Act, HR 1865 - Consolidated Appropriations Act (PL 116-94)
Showing 8 of 16 unique descriptions from filings.
Related Analysis
Related Investigations
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.